WCLC 2025 - Posters & ePosters-EP.17.32 Real-World Disease Impact in First-Line Treated Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 Expression =50%

EP.17.32 Real-World Disease Impact in First-Line Treated Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 Expression =50%

Back to course

Pdf Summary

This study evaluated the real-world impact of advanced non-small cell lung cancer (aNSCLC) on patients in Europe, the US, and Asia, focusing on those with PD-L1 expression ≥50% and lacking actionable genomic alterations (AGAs). Data were collected from December 2023 to May 2024 through a cross-sectional survey involving 433 physicians reporting on 512 patients receiving first-line immunotherapy (IO) alone (66%) or IO combined with chemotherapy (IO+CT, 23%).<br /><br />The median patient age was 69 years, predominantly male (72%), and mostly treated in public hospitals. Most had non-squamous histology (65%) and a history of smoking (88%). Common symptoms across treatment types included cough (62-66%), fatigue (42-53%), and dyspnea (35%). Symptoms were mostly mild to moderate, but fatigue and hoarseness were the most frequent severe symptoms in IO monotherapy and IO+CT groups, respectively.<br /><br />Concomitant conditions commonly affecting patients included chronic pulmonary disease and diabetes without complications, with squamous cell carcinoma patients experiencing higher rates of these conditions. Longer treatment duration correlated with a reduction in some symptoms like cough and wheezing.<br /><br />Patient-reported impairments severely impacting daily life were primarily related to the ability to work (20% IO monotherapy, 27% IO+CT). Quality of life and emotional wellbeing were notably more impaired in the IO+CT group (22% and 16% severe impairment) compared to IO monotherapy (4% and 5%). Physical function and general health were also more severely affected in the IO+CT cohort.<br /><br />Conclusions highlight substantial symptom burden and functional impairment regardless of treatment regimen, with greater quality of life and emotional wellbeing impairments in combination therapy recipients. These findings underscore an unmet need to improve symptom control and overall wellbeing in aNSCLC patients treated with contemporary first-line therapies. Limitations include non-random sampling and exclusion of deceased patients, restricting generalizability.

Asset Subtitle

Delvys Rodriguez-Abreu

Meta Tag

Speaker Delvys Rodriguez-Abreu

Topic Global Health, Health Services, and Health Economics

Keywords

advanced non-small cell lung cancer

aNSCLC

PD-L1 expression ≥50%

first-line immunotherapy

immunotherapy plus chemotherapy

patient-reported outcomes

symptom burden

quality of life

functional impairment

real-world study